Registrational study of ABI-H0731 with NrtI for chronic suppressive therapy in China.
Latest Information Update: 01 Mar 2021
At a glance
- Drugs Vebicorvir (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Sponsors Assembly Biosciences
Most Recent Events
- 25 Feb 2021 Status changed from planning to withdrawn prior to enrolment, according to a BeiGene media release.
- 05 Nov 2020 According to an Assembly Biosciences media release, this study expected to initiate in H1 2021.
- 18 May 2020 New trial record